Vanguard Global Advisers
IOVA icon

Vanguard Global Advisers’s Iovance Biotherapeutics IOVA Stock Holding History

Vanguard Global Advisers’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$900K Buy
216,401
+82,564
+62% +$314K ﹤0.01% 1808
2026
Q1 		$470K Buy
+133,837
New +$428K ﹤0.01% 2078

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.49% 1-Year Est. Return

Vanguard Global Advisers's IOVA Position: Q2 2026 in Review

Vanguard Global Advisers increased its Iovance Biotherapeutics (IOVA) stake by 62% in Q2 2026, buying an estimated $314K and bringing the position to 216,401 shares worth $900K. The position accounts for ﹤0.01% of the portfolio, ranked #1808.

Vanguard Global Advisers first reported a position in IOVA in Q1 2026 and has held it in 2 quarters since. 288 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Vanguard Global Advisers held 216,401 shares of Iovance Biotherapeutics worth $900K as of Q2 2026.
  • Vanguard Global Advisers bought 82,564 Iovance Biotherapeutics shares in Q2 2026, an estimated $314K.
  • Iovance Biotherapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1808 holding.
  • Vanguard Global Advisers first reported a position in Iovance Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 288 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.